Live tape
Top 8, mentions 7d7,412NVDA1,293 mentions▲ +0.09GOOGL1,128 mentions▲ +0.04AVGO1,031 mentions▲ +0.05NKE1,013 mentions+0.02LULU956 mentions▲ +0.03TSLA894 mentions▲ +0.06META581 mentions▲ +0.05MSFT516 mentions▲ +0.06

Equity · Healthcare

NTLA

Intellia Therapeutics, Inc. · NasdaqGM

$13 −0.84% 1D Finazon · prior-day close · Aug 28, 2026
Price · Chart
Our own end-of-day closes 56 sessions
$18 $10 10 Jun 28 Aug

The line runs $12.20 on 10 June through $13 on 28 August, on a scale from $10 to $18. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of NTLA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 56 sessions over that window: $12.20 on 10 June 2026 through $13 on 28 August 2026.

Market cap $1.8B
52-week range $8.04 – $28
Avg volume 437.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

NTLA insider trades

SEC Form 4

NTLA has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 December 2025.

Date Insider Type Shares Value
11 Dec 2025 LEONARD JOHN M President and CEO Sell 88,146 $836K
01 Oct 2025 Schultes Birgit C EVP, Chief Scientific Officer Sell 31 $1K
01 Oct 2025 Dube Michael P VP, Chief Accounting Officer Sell 1,871 $33K
20 Aug 2025 CHASE WILLIAM J Buy 100,000 $1.00M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
12 Dec 2025 LEONARD JOHN M President and CEO Option exercise 8,557 $58K
11 Dec 2025 LEONARD JOHN M President and CEO Option exercise 49,959 $341K

NTLA reported financials

SEC EDGAR XBRL

NTLA reported revenue of $67.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$412.7M.

Figure Reported Period
Revenue $67.7M 31 Dec 2025 fiscal year
Net income −$412.7M 31 Dec 2025 fiscal year
Diluted EPS −$3.81 31 Dec 2025 fiscal year
Total assets $857.2M 30 Jun 2026 at period end
Total equity $727.7M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

NTLA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.80 $8M
31 Mar 2026 Q1 2026 $-0.81 $15M
31 Dec 2025 FY 2025 $-3.81 $68M
30 Sep 2025 Q3 2025 $-0.92 $14M
30 Jun 2025 Q2 2025 $-0.98 $14M
31 Mar 2025 Q1 2025 $-1.10 $17M
31 Dec 2024 FY 2024 $-5.25 $58M
30 Sep 2024 Q3 2024 $-1.34 $9M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

NTLA institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a NTLA position for the quarter ended 30 Jun 2026 — a combined $553.5M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
ARK Investment Management Held (±25%) +16.3% shares 16,875,684 $285.5M
D. E. Shaw & Co. Held (±25%) +12.5% shares 6,443,323 $109.0M
Two Sigma Investments Held (±25%) +11.3% shares 5,235,348 $88.6M
Renaissance Technologies New position 1,400,004 $23.7M
Baker Bros. Advisors New position 930,232 $15.7M
AQR Capital Management Held (±25%) −21.8% shares 492,954 $8.3M
Millennium Management Added +596.2% shares 491,226 $8.3M
Point72 Asset Management Added +47.6% shares 398,463 $6.7M
Citadel Advisors Trimmed −64.1% shares 164,712 $2.8M
Marshall Wace Held (±25%) +19.4% shares 164,078 $2.8M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

NTLA fails-to-deliver

SEC CNS data

On 05 Aug 2026, 846 shares of NTLA failed to deliver (about $10K).

Settlement date Shares failed Notional % of shares out
05 Aug 2026 846 $10K 0.001%
31 Jul 2026 430 $5K <0.001%

Source: SEC fails-to-deliver (CNS) data